Alex Franzusoff
Overview
Explore the profile of Alex Franzusoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puig-Saus C, Sennino B, Peng S, Wang C, Pan Z, Yuen B, et al.
Nature
. 2023 Mar;
615(7953):697-704.
PMID: 36890230
Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells. The large HLA allele diversity and limiting clinical samples have...
2.
Foy S, Jacoby K, Bota D, Hunter T, Pan Z, Stawiski E, et al.
Nature
. 2022 Nov;
615(7953):687-696.
PMID: 36356599
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells. Here we developed a clinical-grade approach based on CRISPR-Cas9 non-viral precision genome-editing to simultaneously knockout the...
3.
Foy S, Mandl S, Dela Cruz T, Cote J, Gordon E, Trent E, et al.
Cancer Immunol Immunother
. 2016 Mar;
65(5):537-49.
PMID: 26961085
The dramatic clinical benefit of immune checkpoint blockade for a fraction of cancer patients suggests the potential for further clinical benefit in a broader cancer patient population by combining immune...
4.
Foy S, Sennino B, Dela Cruz T, Cote J, Gordon E, Kemp F, et al.
PLoS One
. 2016 Feb;
11(2):e0150084.
PMID: 26910562
Poxvirus-based active immunotherapies mediate anti-tumor efficacy by triggering broad and durable Th1 dominated T cell responses against the tumor. While monotherapy significantly delays tumor growth, it often does not lead...
5.
Mandl S, Rountree R, Dela Cruz T, Foy S, Cote J, Gordon E, et al.
J Immunother Cancer
. 2014 Oct;
2(1):34.
PMID: 25328681
Background: PROSTVAC®, an active immunotherapy currently studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC), consists of a heterologous prime-boost regimen with two different poxvirus-based vectors to provoke productive...
6.
Bui M, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, et al.
Vaccine
. 2010 Jul;
28(37):6028-35.
PMID: 20619375
Chromosomal translocations generating the BCR-ABL oncogene cause chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia. The BCR-ABL(T315I) mutation confers drug resistance to FDA-approved targeted therapeutics imatinib mesylate,...
7.
Boehm A, Higgins J, Franzusoff A, Schlom J, Hodge J
Cancer Immunol Immunother
. 2009 Sep;
59(3):397-408.
PMID: 19756595
Purpose: Studies comparing two or more vaccine platforms have historically evaluated each platform based on its ability to induce an immune response and may conclude that one vaccine is more...
8.
Remondo C, Cereda V, Mostbock S, Sabzevari H, Franzusoff A, Schlom J, et al.
Vaccine
. 2008 Dec;
27(7):987-94.
PMID: 19110021
Tumor-associated antigens are weakly immunogenic. Human carcinoembryonic antigen (CEA) is overexpressed on a wide range of human carcinomas and represents an attractive target for cancer immunotherapy. This study analyzes the...
9.
Wansley E, Chakraborty M, Hance K, Bernstein M, Boehm A, Guo Z, et al.
Clin Cancer Res
. 2008 Jul;
14(13):4316-25.
PMID: 18594015
Purpose: Saccharomyces cerevisiae, a nonpathogenic yeast, has been used previously as a vehicle to elicit immune responses to foreign antigens, and tumor-associated antigens, and has been shown to reduce tumor...
10.
Bernstein M, Chakraborty M, Wansley E, Guo Z, Franzusoff A, Mostbock S, et al.
Vaccine
. 2007 Dec;
26(4):509-21.
PMID: 18155327
Recombinant Saccharomyces cerevisiae (yeast) represents a unique and attractive vehicle to deliver antigens in vaccine immunotherapy protocols for cancer or infectious disease, in that it has been shown to be...